A review of GnRH antagonists as treatment for abnormal uterine bleeding-leiomyoma (AUB-L) and their influence on the readiness of service members
D Wright, JW Kim, H Lindsay, WH Catherino - Military Medicine, 2023 - academic.oup.com
Introduction Not too long ago, Lupron Depot®(leuprolide acetate), an injectable
gonadotropin-releasing hormone (GnRH) agonist, was the only Food and Drug …
gonadotropin-releasing hormone (GnRH) agonist, was the only Food and Drug …
Relugolix and elagolix directly inhibit leiomyoma extracellular matrix production in 2-dimesnional and 3-dimensional cell cultures
D Wright, J Britten, M Malik, WH Catherino - F&S Science, 2022 - Elsevier
Objective To determine the effect relugolix and elagolix have on the production of
extracellular matrix (ECM) proteins in human leiomyoma cells. Design Laboratory study …
extracellular matrix (ECM) proteins in human leiomyoma cells. Design Laboratory study …
[引用][C] Rote Hand Brief zur Anwen-dung von 5 mg Ulipristalacetat vom 01.02. 2021
L Kiesel, V der DGGEF - Gynäkologische Endokrinologie, 2021 - Springer
Hintergrund Ulipristalacetat ist ein oral wirksamer, synthetischer, selektiver
Progesteronrezeptor-Modulator (SPRM), welcher einen direkten Effekt auf das Endometrium …
Progesteronrezeptor-Modulator (SPRM), welcher einen direkten Effekt auf das Endometrium …